Diversified Healthcare Trust updated full year 2026 guidance to $0.46 - $0.52 of Normalized FFO per common share and $110,700-$125,700 of Normalized FFO, reflecting a $29,300 incentive management fee, while targeting 5.5x - 6.5x leverage.
DHC · Diversified Healthcare Trust
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $7.03
- Open
- $7.24
- Day range
- $7.00–7.25
- 52-week closing range
- $4.45–9.64
- Average volume, 30 days
- 1.7M
- Short interest
- 12.0M · 4.9% of shares · 8.1 days
- Short volume, last session
- 43%
- Last earnings
- Nov 3, 2026
- Latest filing
- 10-Q · Nov 2
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
DHC reported third-quarter consolidated NOI of $80.8 million, up 27.5%, and raised same-property shop NOI guidance by $5 million at the midpoint to $190 to $200 million while reducing recurring capital expenditure guidance by $10 million.
For the three months ended September 30, 2026, Diversified Healthcare Trust reported a net loss of 50,229 (dollars in thousands) versus 164,040, as NOI rose 27.5% to 80,763 and comparable SHOP occupancy increased to 84.4% from 82.4%.
Diversified Healthcare Trust reported same-property cash basis NOI growth of 25.6% to $77.9 million and Adjusted EBITDAre growth of 28.4% to $73.4 million for the quarter ended September 30, 2026. It lowered full year 2026 Normalized FFO guidance to $110,700 - $125,700.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. DHC reported strong Q2 results with 37.2% YoY same-property SHOP NOI growth and reaffirmed recently raised full-year guidance, while reducing 2026 SHOP occupancy and revenue growth assumptions (offset by improved expense control) and announcing new operator contracts set to begin January 2027.
- + Same-property SHOP NOI grew 37.2% YoY to $52 million with margins expanding 390 bps to 17.3%.
- + Medical office leasing was robust with 477,000 sq ft at 6.7% rent roll-up and 7.1-year weighted average lease term.
- + Full-year 2026 guidance was reaffirmed at raised levels, with SHOP NOI tracking toward high end.
- − SHOP top-line pacing below initial 2026 projections with occupancy gains slower than expected.
- − Q2 shop same-store NOI included a ~$1.5 million one-time expense benefit not expected to repeat.
- − Three known MOB/life science tenant vacates representing ~4.6% of segment annualized revenue, with two effective July 1.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total recurring capital expenditures | $26.15M | FY2026 Q3 | -35.5% |
|
|
|||
| Adjusted EBITDAre non-GAAP | $82.08M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationEBITDAre 66.74M (the result of another reconciliation in this filing)
+2.26M General and administrative expense paid in common shares
+9.99M Incentive management fees
+3.09M Acquisition and certain other transaction related costs
+0K Gain on insurance recoveries
+0K Loss on modification or early extinguishment of debt
+0K Adjustments to reflect DHC's share of Adjusted EBITDAre attributable to a former equity method investment
= Adjusted EBITDAre 82.08M
|
|||
| All Other NOI non-GAAP | 7.24M | the three months ended June 30, 2026 filing | — |
| Average Monthly Rate | $5,715 | the three months ended June 30, 2026 | — |
| Average monthly rate (SHOP, all properties) | $5,693 | Three months ended June 30, 2026 filing | — |
| CAD non-GAAP | 18.52M | three months ended 6/30/2026 | — |
| CAD per common share non-GAAP | $0.08 | three months ended 6/30/2026 | — |
| Cash Basis NOI non-GAAP | $84.23M | the three months ended 6/30/2026 | — |
GAAP → non-GAAP reconciliationNOI 84.44M (the result of another reconciliation in this filing)
-211K Non-cash adjustments
= Cash Basis NOI 84.23M
|
|||
| Communities transitioned to new and existing third party managers | 116 | the three months ended June 30, 2026 filing | — |
| Consolidated NOI | $84.44M | Three Months Ended June 30, 2026 | — |
| EBITDAre non-GAAP | 66.74M | three months ended 6/30/2026 | — |
GAAP → non-GAAP reconciliationEBITDA 63.5M (the result of another reconciliation in this filing)
+629K Loss (gain) on sale of real estate
+0K Impairment of assets
-1.85M Equity in net earnings of investees
+4.46M Share of EBITDAre from unconsolidated joint ventures
+0K Adjustments to reflect DHC's share of EBITDAre attributable to a former equity method investment
= EBITDAre 66.74M
|
|||
| FFO non-GAAP | 25.82M | three months ended 6/30/2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -37.42M
+62.54M Depreciation and amortization
+629K Loss (gain) on sale of real estate
+0K Impairment of assets
-1.85M Equity in net earnings of investees
+1.92M Share of FFO from unconsolidated joint ventures
+0K Adjustments to reflect DHC's share of FFO attributable to a former equity method investment
= FFO 25.82M
|
|||
| FFO per common share non-GAAP | $0.11 | three months ended 6/30/2026 | — |
| Gross Book Value of Unencumbered Properties | $4B | As of June 30, 2026 | — |
| Medical Office and Life Science Portfolio NOI non-GAAP | 23.71M | the three months ended June 30, 2026 filing | — |
| Net debt / total gross assets | 36.1% | As of and For the Three Months Ended 6/30/2026 | — |
| Normalized FFO non-GAAP | $38.9M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationFFO 25.82M (non-GAAP)
+9.99M Incentive management fees
+3.09M Acquisition and certain other transaction related costs
+0K Gain on insurance recoveries
+0K Loss on modification or early extinguishment of debt
+0K Adjustments to reflect DHC's share of Normalized FFO attributable to a former equity method investment
= Normalized FFO 38.9M
|
|||
| Occupancy | 83.1% | the three months ended June 30, 2026 | — |
| Occupancy (SHOP, all properties) | 82.5% | Three months ended June 30, 2026 filing | — |
| Properties | 67 | as of 6/30/2026 (Medical Office and Life Science Portfolio) | — |
| Same Property Cash Basis NOI Medical Office and Life Science Portfolio | $24.05M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationCash Basis NOI 23.67M (non-GAAP)
+385K Cash Basis NOI of properties not included in same property results
= Same property Cash Basis NOI - Medical Office and Life Science Portfolio 24.05M
|
|||
| Same Property Cash Basis NOI SHOP | $51.98M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationCash Basis NOI 53.5M (non-GAAP)
-1.52M Cash Basis NOI of properties not included in same property results
= Same property Cash Basis NOI - SHOP 51.98M
|
|||
| Same property NOI non-GAAP | $51.98M | the three months ended 6/30/2026 | — |
| Same Property Occupancy Medical Office and Life Science Portfolio | 95.8% | Three Months Ended June 30, 2026 | — |
| Same Property Occupancy SHOP | 83.1% | Three Months Ended June 30, 2026 | — |
| Same property SHOP NOI margin | 17.3% | Q2 2026 | — |
| SHOP NOI non-GAAP | 53.5M | the three months ended June 30, 2026 filing | — |
| SHOP Same Property Average Monthly Rate Growth | 6.2% | Three Months Ended June 30, 2026 | — |
| Square feet of new and renewal leasing (Medical Office and Life Science Portfolio) | 477,000 | Three Months Ended June 30, 2026 | — |
| Total capital expenditures | $25.8M | the three months ended June 30, 2026 filing | — |
| Total Liquidity | $266.8M | As of June 30, 2026 | — |
| Units | 22,469 | As of and For the Three Months Ended 6/30/2026 | — |
| Weighted average lease term (Medical Office and Life Science leasing) | 7.1 | Three Months Ended June 30, 2026 | — |
| Weighted average lease term (years, total leases) | 7.1 | Three months ended June 30, 2026 filing | — |
| Weighted average rent change on leasing (Medical Office and Life Science Portfolio) | 6.7% | Three Months Ended June 30, 2026 | — |
| Weighted average rent coverage (triple net leased, all properties) | 2.78 | Three months ended June 30, 2026 filing | — |
| Weighted average rental rate change (by rentable square feet, total leases) | 6.7% | Three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DHC
this stock
Diversified Healthcare Trust
|
$1.70B | +44.9% | +1.6% | — | 4.9% |
|
WELL
Welltower Inc.
|
$178.41B | +31.0% | +35.6% | 105.7 | 2.4% |
|
VTR
Ventas, Inc.
|
$46.01B | +12.4% | +18.5% | 164.2 | 2.8% |
|
OHI
Omega Healthcare Investors Inc
|
$13.97B | +3.6% | +13.2% | 18.4 | 4.8% |
|
AHR
American Healthcare REIT, Inc.
|
$13.37B | +22.4% | +9.1% | 115.2 | 14.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 20
Diversified Healthcare Trust updated full year 2026 guidance to $0.46 - $0.52 of Normalized FFO per common share and $110,700-$125,700 of Normalized FFO, reflecting a $29,300 incentive management fee, while targeting 5.5x - 6.5x leverage.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DHC | -3.6% | -10.7% | -14.4% | -9.6% | +45.0% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +1.9% | -4.4% | -8.7% | -4.4% | +40.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.